Why the study?
Doubts remain regarding the possible benefits or harms of ACE inhibitors and AT1R inhibitors in patients with COVID-19 experiencing pneumonia.
Do angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor 1 (AT1R) inhibitors benefit or harm patients infected by COVID-19 who experience pneumonia?
Do angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor 1 (AT1R) inhibitors benefit or harm patients infected by COVID-19 who experience pneumonia?
Unclear effects of ACE inhibitors and AT1R inhibitors in COVID-19 pneumonia; leaves open need for targeted RCTs before practice change.
The renin-angiotensin system (RAS) plays a main role in regulating blood pressure and electrolyte and liquid balance. Previous evidence suggests that RAS may represent an important target for the treatment of lung pathologies, especially for acute respiratory distress syndrome and chronic fibrotic disease. The scientific community has recently focused its attention on angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor 1 (AT1R) inhibitors and their possible benefit/harms for patients infected by Coronavirus disease (COVID-19) who experience pneumonia, but there are still some doubts about the effects of these drugs in this setting.
No takes yet. Share an insight, caveat, or question.
D’Ardes et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: